EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
European Association for the Study of the Liver.
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.
Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K.
Hepatology. 2016 Jan;63(1):284-306. doi: 10.1002/hep.28280. Epub 2015 Nov 13.
Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019.
GBD 2019 Europe Hepatitis B & C Collaborators.
Lancet Public Health. 2023 Sep;8(9):e701-e716. doi: 10.1016/S2468-2667(23)00149-4.
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ.
Nat Med. 2021 Oct;27(10):1725-1734. doi: 10.1038/s41591-021-01513-4. Epub 2021 Oct 12.
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
Chun HS, Papatheodoridis GV, Lee M, Lee HA, Kim YH, Kim SH, Oh YS, Park SJ, Kim J, Lee HA, Kim HY, Kim TH, Yoon EL, Jun DW, Ahn SH, Sypsa V, Yurdaydin C, Lampertico P, Calleja JL, Janssen H, Dalekos GN, Goulis J, Berg T, Buti M, Kim SU, Kim YJ.
J Hepatol. 2024 Jan;80(1):20-30. doi: 10.1016/j.jhep.2023.09.011. Epub 2023 Sep 19.
Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China.
Yu R, Fan R, Hou J.
Front Med. 2014 Jun;8(2):135-44. doi: 10.1007/s11684-014-0331-5. Epub 2014 May 8.
Meta-analysis: hepatitis B reactivation in patients receiving biological therapy.
El Jamaly H, Eslick GD, Weltman M.
Aliment Pharmacol Ther. 2022 Oct;56(7):1104-1118. doi: 10.1111/apt.17155. Epub 2022 Aug 17.
Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors.
Savaliya BP, Shekouhi R, Mubarak F, Manaise HK, Jimenez PB, Kowkabany G, Popp RA, Popp K, Gabriel E.
World J Gastroenterol. 2024 Jun 28;30(24):3052-3058. doi: 10.3748/wjg.v30.i24.3052.
Hepatitis B Virus Reactivation Potentiated by Biologics.
Ogawa E, Wei MT, Nguyen MH.
Infect Dis Clin North Am. 2020 Jun;34(2):341-358. doi: 10.1016/j.idc.2020.02.009. Epub 2020 Apr 23.
Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir-induced renal dysfunction.
Chotiyaputta W, Poosanasuwansri K, Kiattisunthorn K, Chainuvati S, Tanwandee T.
J Viral Hepat. 2021 Feb;28(2):364-372. doi: 10.1111/jvh.13420. Epub 2020 Nov 2.
